Bausch Health Companies (BHC): Price to Earnings Adjusted for Growth Rate

Bausch Health Companies (BHC) management aims to optimize the corporate structure and reduce the debt burden to unlock asset value. The growth stock attractiveness indicator links these processes to fundamentals, where the value of 0.00 represents the most recent figure. Cash generation efficiency is constrained by high leverage, while pricing policy balances premium patents against fierce competition in the generics sector.

Bausch Health Corp - BHC PEG Multiple (period 07/04/2022 - 11/11/2026)

Metric breakdowns and analytics for Bausch Health Companies (BHC)

- share price and consensus valuation forecast:

Price Performance Chart Bausch Health Companies Inc.|BHC - Price Target Chart

- stock exchange capitalization data:

Market Value Valeant Pharmaceuticals|BHC - Total Company Value

- shareholders' equity book value data:

Net Assets per Single Share Bausch Health|BHC - Book Capitalization|Capitalization to Book Value Ratio bauschhealth.com|BHC - Company Total Assets

- issuer credit burden and liquidity indicators:

- financial results and valuation multiples details:

BHC - Net Income|Projected Future Earnings Bausch Health Companies|BHC - Price to Earnings Ratio|Market Cap to Projected Earnings Bausch Health Corp|BHC - PEG Multiple|Enterprise Value to EBITDA Ratio Valeant Pharmaceuticals|BHC - Operating profit EBITDA|Earnings per share for the trailing year Bausch Health|BHC - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months bauschhealth.com|BHC - Earnings growth in current year|Expected earnings per share trend next year Bausch Health Companies

General company analysis:Bausch Health Companies

Core merchandise of Bausch Health Companies Inc.

The PEG ratio compares the P/E multiple with earnings growth rates, making it possible to identify undervalued assets where the business value grows more slowly than its actual income. By analyzing P/E dynamics relative to earnings growth, an investor can see how the stable sales of ophthalmology drugs from Bausch Health Companies (BHC) balance litigation risks, turning moderate development into a potential driver for the long-term recovery of the share price.

Competing companies